Pegbio
Hefei, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developer of long-acting biologics for metabolic diseases using advanced drug delivery platforms.
Metabolic
Technology Platform
A proprietary drug delivery platform centered on PEGylation technology to develop long-acting versions of biologic therapeutics.
Opportunities
Near-term potential to commercialize long-acting therapies in the vast Chinese metabolic disease market.
Risk Factors
Commercial risk of launching differentiated but not novel products in a market with rapidly evolving standard-of-care.
Competitive Landscape
Competes in the long-acting metabolic drug segment, facing pressure from both originator companies and other formulation-focused biotechs.